Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...

For many years, astrocytes were seen as simple support cells in the brain. Today, that picture is changing fast.

Despite advances, the roles of genetics and microenvironment in CLL are not fully understood, and curative treatments may hinge on a dual approach targeting both.

Combination therapy of osimertinib and datopotamab deruxtecan shows promising efficacy in advanced NSCLC, warranting further ...

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and a leading cause of cancer-related deaths worldwide ...

This article explores the complex roles of cytokine networks in the development and progression of autoimmune diseases.

With tremendous social and economic costs, dementia is now the seventh leading cause of death globally, affecting 57 million ...

Star Overdrive Review. Star Overdrive is a third-person adventure game heavily inspired by The Legend of Zelda: Breath of the ...

Adding lurbinectedin to atezolizumab as first-line maintenance improved PFS and OS in patients with ES-SCLC in the phase 3 ...

Discover the subtle vitamin B12 deficiency symptoms that mimic other conditions and learn why this nutritional shortage often ...

Tumors are complex systems characterized by variations across genetic, transcriptomic, phenotypic, and microenvironmental ...

Circle Pharma receives US FDA orphan drug designation for its CID-078 to treat small cell lung cancer: South San Francisco, California Wednesday, June 18, 2025, 18:00 Hrs [IST] So ...